Compare Gilead Sciences, Inc. (GILD) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Manulife Financial Corporation — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Manulife Financial Corporation trades at $43.15 (market cap $70.81B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| GILD | MFC | |
|---|---|---|
Market Cap | $163.51B | $70.81B |
Sector | Health | Financials |
52-Week High | $155.80 | $43.07 |
52-Week Low | $108.22 | $29.90 |
Enterprise Value | $178.05B | $67.37B |
Dividend Yield | 2.49% | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Manulife Financial (MFC) trades at $41.69, up 0.97% on the day and near its 52-week high, reflecting strong technical momentum. The company reported mixed Q1 2026 earnings but has beaten estimates in two of the last three quarters, with revenue growing to $53.01B in 2025. Analyst consensus is bullish with 8 Buy ratings and no Sell recommendations, supported by a solid 12.07% net income margin and 13.14% ROE. Recent news highlights AI advancements and a strong Asia business, though regulatory scrutiny on certain products presents a watch item.
The outlook for MFC is positive, driven by earnings growth in Asia, strategic AI investments, and a robust capital position. Key opportunities include expansion in wealth management and continued dividend returns. Primary risks involve regulatory pressures in Hong Kong, volatility in global wealth segments, and potential margin compression from competitive and macroeconomic forces.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
